On March 29, 2022, ScreenPro Security Inc. (CSE: SCRN) (OTCQB: SCRSF) (“ScreenPro” or the “Company”) announced that the Company’s wholly owned subsidiary, Add Biomedical Inc. (Add Bio), is strengthening its library of intellectual property (IP). The Company has further applied for the Cancer Antigen (CA) 15-3 rapid testing kit for breast cancer screening to the United States Patent and Trademark Office.
It appears that management are loading up on shares in the recent days. Judging by the stock market, investors see more good times ahead for profits in 2022. After a decline in share price at the start of the year; management seem to have increased the numbers contract secured for Covid-19 testing. The more contagious BA.2 subvariant of Omicron is now the dominant version of the virus in several provinces in Canada. Amid loosened public health measures experts say that number of cases may rise to same levels as past waves. Testing for Covid-19 will probably remain for the next 3 years or more.
Canada is heading towards a potential sixth COVID-19 wave, experts say, as cases and hospitalizations have started to creep back up again across the country.
While average daily case counts have levelled off nationally, there continues to be regional variability across the country with several jurisdictions reporting increases, said Dr. Theresa Tam, Canada’s chief public health officer in her latest weekly update on Friday.